home / stock / vyne / vyne news

VYNE News and Press, VYNE Therapeutics Inc Com From 08/10/22

Stock Information
Company Name: VYNE Therapeutics Inc Com
Stock Symbol: VYNE
Market: NASDAQ
Website: vynetherapeutics.com
Menu
VYNE VYNE Quote VYNE Short VYNE News VYNE Articles VYNE Message Board
Get VYNE Alerts

News, Short Squeeze, Breakout and More Instantly...
VYNE - Vyne sheds 31% as mid-stage trial for atopic dermatitis candidate fails

The shares of nano-cap pharma VYNE Therapeutics ( NASDAQ: VYNE ) fell ~31% in the pre-market Wednesday after the company announced that its atopic dermatitis candidate FMX114 failed to reach the main goal in a mid-stage study. The Phase 2a segment of a Phase 1b/2a clinic...
VYNE - VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...

VYNE - VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...

VYNE - VYNE Therapeutics rises on ending enrollment in mid-stage trial of itchy skin gel FMX114

VYNE Therapeutics (NASDAQ:VYNE) on Friday said it had completed enrollment in its phase 2a trial of its FMX114 gel to treat mild-to-moderate atopic dermatitis, an itchy inflammation of the skin. VYNE stock rose 7.7% to $0.55 in premarket trading. With enrollment done, VYNE expects t...
VYNE - VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions,...

VYNE - VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, ...

VYNE - VYNE Therapeutics Non-GAAP EPS of $0.10 beats by $0.25, revenue of $0.18M misses by $0.19M

VYNE Therapeutics press release (NASDAQ:VYNE): Q1 Non-GAAP EPS of $0.10 beats by $0.25. Revenue of $0.18M (-21.7% Y/Y) misses by $0.19M. “Looking ahead, we plan to report Phase 2a safety and efficacy results for FMX114 by the end of the second quarter. We are pleased with our toxicolog...
VYNE - VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBET TM BET inhibitor p...

VYNE - VYNE Hosting Key Opinion Leader Event on Novel InhiBET(TM) BET Inhibitor Platform

BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, ...

VYNE - VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10th

BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, ...
Previous 10 Next 10